<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00367952</url>
  </required_header>
  <id_info>
    <org_study_id>AVX-201E</org_study_id>
    <nct_id>NCT00367952</nct_id>
  </id_info>
  <brief_title>A Long Term, Safety Study of Apricitabine in HIV-infected Subjects</brief_title>
  <official_title>An Open Label Long Term Safety Extension Study of Apricitabine in Treatment-experienced HIV-1 Infected Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avexa</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avexa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will examine how safe and effective apricitabine is when given long term (as
      ongoing treatment) to HIV patients who have already completed the AVX-201 trial
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An ongoing study (AVX-201) is examining the safety and efficacy of apricitabine compared to
      3TC in HIV patients who are failing therapy containing 3TC and have the presence of the M184V
      mutation in reverse transcriptase. This extension study (AVX-201E) is available to patients
      who complete the AVX-201 protocol.

      Patients will continue to receive apricitabine open label for a further 96 weeks (making a
      total of 144 weeks from starting AVX-201) in addition to an optimised background. Safety
      markers and efficacy markers will be followed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to virological failure (DHSS definition)</measure>
    <time_frame>week 144</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>incidence of AEs and laboratory abnormalities</measure>
    <time_frame>Week 144</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>time to withdrawal due to AEs</measure>
    <time_frame>Week 144</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline HIV RNA</measure>
    <time_frame>weeks 72, 96, 120, and 144</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with plasma HIV RNA &lt;400 and &lt;50 copies/ml</measure>
    <time_frame>at weeks 72, 96, 120, and 144</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline and change in ratio of CD4+ and CD8+ counts</measure>
    <time_frame>at weeks 72, 96, 120, and 144</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>ATC 800mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800mg ATC BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>apricitabine</intervention_name>
    <description>800mg apricitabine twice daily orally for 96 weeks</description>
    <arm_group_label>ATC 800mg BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Completed AVX-201 protocol, Plasma HIV RNA &lt;5000 copies/ml, CD4 cells &gt;50

        Exclusion Criteria:

          -  Pregnant or breastfeeding females, withdrawal from AVX-201
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan W Cox, Ph D</last_name>
    <role>Study Director</role>
    <affiliation>Avexa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Avexa (co-ordinating sites in Australia and Argentina)</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3121</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2006</study_first_submitted>
  <study_first_submitted_qc>August 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2006</study_first_posted>
  <last_update_submitted>June 22, 2011</last_update_submitted>
  <last_update_submitted_qc>June 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2011</last_update_posted>
  <responsible_party>
    <name_title>Susan Cox</name_title>
    <organization>Avexa</organization>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>apricitabine</keyword>
  <keyword>drug resistance</keyword>
  <keyword>reverse transcriptase</keyword>
  <keyword>lamivudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

